Genentech?s plan to restrict the availability of Avastin so doctors cannot use it instead of a more expensive medicine for eye disease will cost taxpayers $1 billion to $3 billion a year.
From: www.nytimes.com
Senator Criticizes Genentech?s Limits on a Cheaper Drug
Posted by Ruslan Abuzant at 7:58 PM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment